lorlatinib
Sign in to saveLorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is an orally administered inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), two enzymes that play a role in the development of cancer. It was developed by Pfizer.
Key facts
- Drug.image
- Lorlatinib Structure.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Lorbrena, Lorviqua
- Drug.MedlinePlus
- a619005
- Drug.DailyMedID
- Lorlatinib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.class
- Antineoplastic
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- ED05
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- 81%
- Drug.protein_bound
- 66%
- Drug.metabolism
- Mainly CYP3A4 and UGT1A4
via Wikipedia infobox
Research
845 papers- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.The New England journal of medicine · 2020
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
- A pragmatic guide for management of adverse events associated with lorlatinib.Lung cancer (Amsterdam, Netherlands) · 2024
- Lorlatinib.2012
- Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.The Lancet. Respiratory medicine · 2023
via PubMed
Article
14 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Society and culture
- Legal status
- Research
- References
- External links
Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is an orally administered inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), two enzymes that play a role in the development of cancer. It was developed by Pfizer.
The most common adverse reactions include edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia, and cough.